Biotech ePRO: HEOR-ready evidence from Phase I/II

ePRO for biotech: capture economic evidence from day one

Secure data integrity and economic value data before the Phase III evidence gap closes.

Generate submission-ready evidence from Phase I/II

Safety data alone no longer wins Series B funding or Phase III partnerships. Payers and partners now expect economic value evidence — quality-of-life data, tolerability profiles, and HEOR readiness — built into early-phase studies.

This one-pager covers how Castor’s ePRO helps biotech sponsors capture that evidence from Phase I/II, without adding operational complexity.

Inside: how to build HEOR readiness from day one, the audit-proof data architecture that satisfies ICH E6(R3), and how Castor achieves more than 92% participant compliance.